Inari Medical, Inc. (NASDAQ:NARI) Receives $58.89 Average PT from Brokerages

Inari Medical, Inc. (NASDAQ:NARIGet Free Report) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $60.50.

A number of equities research analysts recently weighed in on NARI shares. Truist Financial boosted their price objective on Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research report on Tuesday, October 29th. Leerink Partners initiated coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Finally, Piper Sandler raised their price target on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a report on Tuesday, October 29th.

Get Our Latest Report on Inari Medical

Insiders Place Their Bets

In other news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the sale, the director now directly owns 601,233 shares in the company, valued at $27,067,509.66. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at approximately $22,265,500. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 143,000 shares of company stock worth $7,022,400. 10.60% of the stock is currently owned by company insiders.

Institutional Trading of Inari Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its holdings in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after acquiring an additional 473 shares in the last quarter. KBC Group NV raised its holdings in shares of Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after purchasing an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in shares of Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after purchasing an additional 522 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Inari Medical during the second quarter worth about $104,000. Institutional investors own 90.98% of the company’s stock.

Inari Medical Stock Performance

NASDAQ NARI opened at $56.16 on Friday. The firm’s fifty day moving average price is $49.03 and its two-hundred day moving average price is $47.99. The stock has a market cap of $3.29 billion, a PE ratio of -41.60 and a beta of 0.97. Inari Medical has a fifty-two week low of $36.73 and a fifty-two week high of $67.10.

Inari Medical Company Profile

(Get Free Report

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.

Recommended Stories

Analyst Recommendations for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.